- Home
- NAZ vs PLX Comparison
NAZ vs PLX Comparison
Compare NAZ & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAZ
- PLX
- Stock Information
- Founded
- NAZ 1992
- PLX 1993
- Country
- NAZ United States
- PLX United States
- Employees
- NAZ N/A
- PLX N/A
- Industry
- NAZ Finance/Investors Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAZ Finance
- PLX Health Care
- Exchange
- NAZ Nasdaq
- PLX Nasdaq
- Market Cap
- NAZ 137.5M
- PLX 127.4M
- IPO Year
- NAZ N/A
- PLX 1998
- Fundamental
- Price
- NAZ $11.76
- PLX $1.82
- Analyst Decision
- NAZ
- PLX Strong Buy
- Analyst Count
- NAZ 0
- PLX 1
- Target Price
- NAZ N/A
- PLX $15.00
- AVG Volume (30 Days)
- NAZ 18.3K
- PLX 642.3K
- Earning Date
- NAZ 01-01-0001
- PLX 08-14-2025
- Dividend Yield
- NAZ 3.69%
- PLX N/A
- EPS Growth
- NAZ N/A
- PLX N/A
- EPS
- NAZ N/A
- PLX 0.08
- Revenue
- NAZ N/A
- PLX $61,948,000.00
- Revenue This Year
- NAZ N/A
- PLX $14.53
- Revenue Next Year
- NAZ N/A
- PLX $75.77
- P/E Ratio
- NAZ N/A
- PLX $23.57
- Revenue Growth
- NAZ N/A
- PLX 62.79
- 52 Week Low
- NAZ $9.22
- PLX $0.99
- 52 Week High
- NAZ $11.37
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- NAZ 47.17
- PLX 66.24
- Support Level
- NAZ $11.62
- PLX $1.52
- Resistance Level
- NAZ $11.99
- PLX $1.69
- Average True Range (ATR)
- NAZ 0.09
- PLX 0.08
- MACD
- NAZ -0.02
- PLX 0.02
- Stochastic Oscillator
- NAZ 37.84
- PLX 92.31
About NAZ Nuveen Arizona Quality Municipal Income Fund
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. Its primary investment objective is to provide current income exempt from both regular federal income taxes and Arizona individual income taxes. The fund's secondary objective is to enhance the portfolio value relative to the Arizona municipal bond market through investments in tax-exempt Arizona Municipal Obligations that, in the opinion of the Fund's investment adviser, are underrated or undervalued or represent municipal market sectors that are undervalued.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.